Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
iStock 12838137902 - Business Express

Deepbridge appoints new Senior Investment Director


  • Life sciences investment team boosted by Investment Directors appointment
  • Dr Andy Round to support and grow portfolio of companies across UK

Venture capital investment specialists, Deepbridge Capital, today announces the appointment of Dr Andy Round as Senior Investment Director.

As an experienced life sciences investment specialist, most recently as Director and Head of Healthcare at Praetura Ventures and previously at both Maven Capital Partners and MSIF, Dr Round will be working within Deepbridge’s Life Sciences Investment Team which manages the Deepbridge Life Sciences EIS fund.

This recruitment forms part of Deepbridge’s wider restructuring programme, following the promotion of Ben Carter to Head of Life Sciences and the additions of Simon Thelwall-Jones, David Blake and Oliver Wheatley to Deepbridge’s Tech Investment Team; with Dr Savvas Neophytou as Chief Investment Officer.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

With over £230m invested to date and over 75% of investment being outside of London, Deepbridge is one of the most active regional early-stage investors in the UK; reporting a record year of fundraising during the 2021/22 tax year, supporting investee companies within the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS funds.

Ian Warwick, Managing Partner at Deepbridge, commented; “My colleagues and I have known Andy for many years, having co-invested with Andy on numerous occasions, so we are delighted that he has now joined Deepbridge; which is testament to the quality of the life sciences companies in our portfolio.

“Despite the uncertainty surrounding the global economy, the UK continues to produce great life sciences and tech innovations which require funding to grow and become the leading companies of tomorrow. This is why the Enterprise Investment Scheme is such a crucial and generous scheme, which is the envy of the world.”

Ben Carter, Investment Director, Head of Life Sciences, added; “Our objective within the Deepbridge Life Sciences Investment Team is to identify, select and proactively support the very best early-stage life sciences opportunities across the UK. Andy’s domain expertise and wealth of experience will be an invaluable addition to our team as we seek to grow the great medtech, pharma, biotech and digital healthcare companies of tomorrow.”

Recent Post: